The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M09 | Other drugs for disorders of the musculo-skeletal system | |
| 3 | M09A | Other drugs for disorders of the musculo-skeletal system | |
| 4 | M09AX | Other drugs for disorders of the musculo-skeletal system | |
| 5 | M09AX09 |
| Active Ingredient | Description | |
|---|---|---|
| Onasemnogene abeparvovec |
Onasemnogene abeparvovec is a gene therapy designed to introduce a functional copy of the survival motor neuron gene (SMN1) in the transduced cells to address the monogenic root cause of the disease. By providing an alternative source of SMN protein expression in motor neurons, it is expected to promote the survival and function of transduced motor neurons. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZOLGENSMA Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
